Celldex Therapeutics (NASDAQ:CLDX) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a hold rating to a buy rating in a research report released on Tuesday, ValuEngine reports.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a buy rating and issued a $19.00 target price on shares of Celldex Therapeutics in a report on Monday, November 11th. Zacks Investment Research raised shares of Celldex Therapeutics from a hold rating to a buy rating and set a $2.25 price target on the stock in a research note on Wednesday, October 9th.

Shares of CLDX stock opened at $2.53 on Tuesday. The company has a market cap of $38.71 million, a price-to-earnings ratio of -0.37 and a beta of 3.42. The stock has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.43. Celldex Therapeutics has a 12-month low of $2.01 and a 12-month high of $11.63. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.01.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.09. Celldex Therapeutics had a negative return on equity of 43.03% and a negative net margin of 1,119.84%. The firm had revenue of $0.55 million for the quarter, compared to the consensus estimate of $1.26 million. On average, equities analysts forecast that Celldex Therapeutics will post -3.85 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cresset Asset Management LLC acquired a new stake in shares of Celldex Therapeutics in the 2nd quarter worth approximately $1,227,000. Renaissance Technologies LLC raised its stake in shares of Celldex Therapeutics by 67.4% during the 2nd quarter. Renaissance Technologies LLC now owns 912,285 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 367,179 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Celldex Therapeutics by 82.0% in the 2nd quarter. Acadian Asset Management LLC now owns 267,557 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 120,519 shares in the last quarter. BlackRock Inc. boosted its position in shares of Celldex Therapeutics by 12.5% in the 2nd quarter. BlackRock Inc. now owns 340,938 shares of the biopharmaceutical company’s stock worth $914,000 after buying an additional 37,820 shares in the last quarter. Finally, A.R.T. Advisors LLC grew its stake in Celldex Therapeutics by 70.1% in the 2nd quarter. A.R.T. Advisors LLC now owns 52,741 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 21,741 shares during the last quarter. Institutional investors own 24.50% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

See Also: Closed-End Mutual Funds (CEFs)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit